STOCK TITAN

Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Acrivon Therapeutics (ACRV) reported a narrower third-quarter net loss and expanded into immunology and inflammation through acquired drug programs. Net loss was $17.897 million, or $0.42 per share, versus $18.234 million, or $0.47 per share, a year earlier. Cash, cash equivalents and investments totaled $77.8 million at September 30, 2026; the company expects funding to last into the fourth quarter of 2027.

The acquisitions added Phase 2-ready JAK1 inhibitor ACR-525, targeting eosinophilic esophagitis, and a preclinical PKCθ inhibitor program. Early ACR-2316 cancer data included confirmed complete and partial responses, with transient, asymptomatic neutropenia reported. Acrivon expects an ACR-368 Phase 2b interim analysis in the fourth quarter of 2026 and plans an FDA application to begin ACR-7280 clinical testing in the first half of 2027.

Loading...
Loading translation...
18 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash, cash equivalents and investments of $77.8 million are expected to fund operations into fourth-quarter 2027.
  • Moderate pointACR-525 acquisition adds a Phase 2-ready JAK1 inhibitor targeting eosinophilic esophagitis.
  • Moderate pointPKCθ program acquisition adds preclinical oral inhibitor candidates for T-cell-driven inflammatory disorders.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.ACR-2316 dose-expansion enrollment and data generation are targeted to prioritize a Phase 2 registrational path by mid-2027.
  • Minor pointThird-quarter net loss narrowed to $17.897 million from $18.234 million; loss per share fell to $0.42 from $0.47.
13 minor points
  • Minor pointACR-525 Phase 1 studies showed no serious adverse events and dose-dependent inhibition of inflammatory biomarker CXCL10.
  • Minor pointACR-2316 monotherapy produced confirmed complete and partial responses in heavily pretreated, AP3-predicted cancer types.
  • Minor pointACR-2316 lung cancer patients included several remaining on treatment for over 73 weeks.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ACR-2316 expansion is planned to include pancreatic ductal adenocarcinoma.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ACR-368 Phase 2b interim analysis and an OncoSignature-positive endometrial cancer update are expected in fourth-quarter 2026.
  • Minor pointACR-7280 produced complete tumor regression in aggressive acute myeloid leukemia animal models.
  • Minor pointACR-7280 studies supporting clinical development in acute myeloid leukemia and peripheral T-cell lymphoma are underway.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ACR-7280 FDA application to begin clinical testing is planned for the first half of 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.PKCθ lead candidates are targeted to advance toward studies supporting clinical testing in first-half 2027.
  • Minor pointThird-quarter general and administrative expenses decreased to $3.971 million from $6.039 million a year earlier.
  • Minor pointNine-month net loss narrowed to $54.903 million from $58.920 million; loss per share fell to $1.33 from $1.53.
  • Minor pointNine-month research and development expenses decreased to $43.557 million from $45.244 million a year earlier.
  • Minor pointNine-month general and administrative expenses decreased to $13.531 million from $18.754 million a year earlier.

Negative

  • Minor pointThird-quarter research and development expenses increased to $14.547 million from $13.648 million a year earlier.
  • Minor pointACR-2316 safety findings included transient, asymptomatic neutropenia, a decrease in infection-fighting white blood cells.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ACR-368 enrollment completion in Arm 3 or Arm 4 depends on the interim readout, targeting fourth-quarter 2026.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ACR-525 Phase 2 trial design still requires FDA alignment, targeted for first-quarter 2027.
  • Minor pointThird-quarter interest income decreased to $0.748 million from $1.506 million a year earlier.
3 minor points
  • Minor pointNine-month interest income decreased to $2.597 million from $5.232 million a year earlier.
  • Minor pointThird-quarter other expense increased to $0.127 million from $0.053 million a year earlier.
  • Minor pointNine-month other expense increased to $0.412 million from $0.154 million a year earlier.

News Explained

Acrivon plans to expand ACR-2316 testing to pancreatic ductal adenocarcinoma, adding another cancer type to the program; the release describes a planned expansion, not a completed study change.

Key Figures

Net loss: $17.9 million vs. $18.2 million Research and development expenses: $14.5 million vs. $13.6 million General and administrative expenses: $4.0 million vs. $6.0 million +3 more
Net loss
$17.9 million vs. $18.2 million
Three months ended September 30, 2026 vs. the same period in 2025
Research and development expenses
$14.5 million vs. $13.6 million
Third quarter 2026 vs. the same period in 2025
General and administrative expenses
$4.0 million vs. $6.0 million
Third quarter 2026 vs. the same period in 2025
Cash, cash equivalents and investments
$77.8 million
As of September 30, 2026; expected to fund operations into the fourth quarter of 2027
Treatment duration
Over 73 weeks
Several heavily pretreated lung cancer patients receiving ACR-2316
Interim analysis timing
Fourth quarter of 2026
Expected prespecified interim analysis of the ACR-368 Phase 2b study

Previous Earnings Reports

1 past event · Latest: Nov 13
Same Type 1 event
  1. Nov 13

    Quarterly results

    24h Move
    +8.2%

    Reported lower year-over-year Q3 net loss, cash runway into Q2 2027, and continued oncology program progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

jak1 inhibitor, eosinophilic esophagitis, neutropenia, ind-enabling studies, +1 more
5 terms
jak1 inhibitor medical
"a Phase 2-ready, oral, highly selective JAK1 inhibitor"
A JAK1 inhibitor is a type of drug that blocks the activity of Janus kinase 1 (JAK1), an enzyme inside cells that helps transmit signals from certain immune-system and inflammatory receptors to the cell’s nucleus. By selectively reducing JAK1 signaling, these medicines aim to lower inflammation and immune activation in conditions such as autoimmune diseases and certain inflammatory disorders; their selectivity distinguishes them from inhibitors that also target JAK2, JAK3, or TYK2, which can cause different effects and side‑effect profiles. Because JAK1 is part of normal immune and blood‑cell regulation, inhibiting it can reduce disease‑related inflammation but also carries risks such as increased infection and altered blood counts, which are evaluated in regulatory and clinical contexts.
eosinophilic esophagitis medical
"targeted as an attractive first indication for this Phase 2-ready"
A chronic allergic condition in which a type of white blood cell builds up in the tube that carries food from the mouth to the stomach, causing inflammation, difficulty swallowing and chest or throat pain; think of it as sticky residue narrowing a pipe. It matters to investors because prevalence, diagnostic rates and treatment options drive demand for drugs, tests and procedures, and clinical or regulatory news can quickly change revenue and valuation for healthcare companies working on therapies or diagnostics.
neutropenia medical
"primarily limited to transient, asymptomatic, mechanism-based neutropenia"
Neutropenia is a medical condition where the blood has an unusually low number of neutrophils, the white blood cells that act like the body’s front-line security guards against bacterial and fungal infections. For investors, it matters because neutropenia can signal safety or tolerability problems for drugs or treatments, driving clinical trial setbacks, regulatory scrutiny, additional monitoring costs, or label warnings that can influence a company’s commercial outlook and stock value. Monitoring for neutropenia is a common part of assessing medical risk and long-term financial impact.
ind-enabling studies regulatory
"IND-enabling studies are underway to support initial clinical development"
Ind-enabling studies are early research efforts that test whether a new drug or treatment is safe and effective enough to move forward in development. They are like preliminary tests to ensure a product works as intended before investing more resources into large-scale trials. For investors, these studies are important because successful results can signal potential progress toward bringing a new product to market, impacting its future value.
recist 1.1 medical
"confirmed complete and partial responses (RECIST 1.1)"
RECIST 1.1 is a standardized set of rules used in cancer clinical trials to measure how solid tumors respond to treatment by tracking changes in size on medical scans. Think of it as a consistent ruler and scorecard that tells doctors and regulators whether a drug is shrinking tumors, keeping them stable, or allowing them to grow. Investors care because RECIST-based results are common primary endpoints that influence regulatory decisions, trial success, and a therapy’s commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach

AI-driven AP3 platform was used for profiling against approved JAK inhibitors to identify recently acquired ACR-525, a Phase 2-ready, potentially best-in-class, highly selective JAK1 inhibitor, and a differentiated preclinical PKCθ program

Late-breaking oral plenary presentation of early Phase 1/2 clinical results in AP3-predicted tumor types for ACR-2316, a differentiated, first-in-class WEE1/PKMYT1 inhibitor, at the upcoming 38th EORTC-NCI-AACR symposium

Prespecified Phase 2b interim analysis of ACR-368, a selective CHK1/2 inhibitor, in all-comer serous endometrial cancer (EC) treatment arms expected in fourth quarter of 2026

Cash, cash equivalents, and marketable securities of $77.8 million as of September 30, 2026, expected to fund operations into fourth quarter of 2027

WATERTOWN, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative AI-driven Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today reported financial results for the third quarter ended September 30, 2026 and reviewed recent business highlights.

“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon. “I&I is particularly well-suited for our AP3 precision medicine approach. We acquired ACR-525 after identifying it as a potentially best-in-class JAK1 inhibitor using our AI-driven AP3 platform for extensive profiling head-to-head against approved JAK inhibitors and dupilumab. Based on this, eosinophilic esophagitis is targeted as an attractive first indication for this Phase 2-ready, oral, highly selective JAK1 inhibitor. The transaction also included a differentiated preclinical PKCθ program for T-cell driven I&I disorders. Additionally, we remain on track for the prespecified interim analysis of the ACR-368 Phase 2 registrational-intent trial. For ACR-2316, our highly differentiated, first-in-class WEE1/PKMYT1 inhibitor in Phase 1/2 dose expansion, we have observed a very favorable safety profile and exceptionally long-lasting clinical benefit across AP3 predicted tumors already during dose escalation. Of note, these include heavily pretreated lung cancers where several patients are on treatment for over 73 weeks now, and where we also have a confirmed complete response. Details of these exciting data will be presented by Dr. Tim Yap as a late-breaking oral plenary presentation at the upcoming Tri-Meeting. ACR-2316 will also be tested as single agent in pancreatic ductal adenocarcinoma based on public data showing WEE1 is synthetic lethal in K-Ras & p53 mutated context. Similar to ACR-368, we have shown that ACR-2316 has strong synergy with immune checkpoint inhibitors and Topo1 inhibitors, providing for attractive combination opportunities. Finally, we also nominated a potential first-in-class, oral CDK11 inhibitor, ACR-7280, identified through the AP3 platform, to advance into IND-enabling studies and be developed in the AP3-predicted tumor type AML.”

Recent Highlights

Immunology and Inflammation Pipeline

  • Acquired ACR-525, an oral, potentially best-in-class JAK1 inhibitor, identified through extensive profiling with the AI-driven AP3 platform, which showed favorable selectivity and attractive pathway effects compared to JAK1 inhibitors
    • Two Phase 1 studies in healthy volunteers demonstrated a favorable safety profile with no observed serious adverse events and dose-dependent inhibition of CXCL10, a clinically relevant inflammatory JAK pathway biomarker. These clinical data are complemented by preclinical findings that ACR-525, like dupilumab, prevents IL-13 -driven esophageal epithelial barrier dysfunction, a cardinal symptom in eosinophilic esophagitis (EoE), while only ACR-525 also prevents oncostatin M-driven barrier dysfunction. AP3 profiling characterized ACR-525 as a highly selective JAK1 inhibitor with minimal off-target effects compared to approved JAK inhibitors and confirmed the broader cellular effects compared to dupilumab.
    • Phase 2-ready ACR-525 is targeted for clinical development in EoE with a tablet for oral suspension formulation designed specifically for patients with difficulty swallowing
    • Selectivity and oral availability of ACR-525 provides rationale for broad opportunity in inflammatory bowel disease and other immune disorders as a single agent and in combination with approved I&I therapies
  • Acquired a preclinical inhibitor program targeting PKCθ with highly selective, oral lead series. PKCθ is a T-cell signaling kinase central to T-cell activation in I&I models.
  • Held a corporate webcast event with EoE Key Opinion Leader experts Evan Dellon, M.D., M.P.H., from the University of North Carolina at Chapel Hill and Arjan Bredenoord, M.D., Ph.D., from Amsterdam University Medical Center, to review the data with ACR-525 and its differentiated profile as a potentially attractive treatment for EoE

ACR-368: CHK1/2 Inhibitor

  • Continued dosing patients across both U.S. and European clinical sites in the two all-comer serous EC arms (Arm 4 single agent and Arm 3 with ultra-low dose gemcitabine sensitization) of the registrational-intent Phase 2b study, which is on track for an upcoming prespecified interim analysis

ACR-2316: Oral WEE1/PKMYT1 Inhibitor

  • Data on the safety, dose optimization, and early clinical activity in AP3-predicted tumor types, including lung cancer, from the dose escalation of the Phase 1/2 study to be featured in a late-breaking oral plenary presentation at the 38th EORTC-NCI-AACR Symposium by Timothy A. Yap, MBBS, Ph.D., FRCP, professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center
    • Data showed long-lasting clinical benefit and/or activity, including confirmed complete and partial responses (RECIST 1.1) with ACR-2316 monotherapy in heavily pretreated, AP3-predicted tumor types, including endometrial and lung cancers
    • Favorable, differentiated safety profile to date, primarily limited to transient, asymptomatic, mechanism-based neutropenia
  • Data showing that AP3 uncovers differential mechanisms driving superior activity of ACR-2316 accepted for poster presentation at the 38th EORTC-NCI-AACR Symposium
  • Subjects with molecularly-defined lung, endometrial, ovarian, cervical, and esophago-gastric junction cancers included in expansion phase
  • Activity in K-Ras pathway mutated cancers and reported synthetic lethality for WEE1 inhibition in K-Ras gain-of-function and TP53 loss-of-function tumors support expansion of study to include pancreatic ductal adenocarcinoma, a tumor type predicted by AP3 to be sensitive to ACR-2316
  • Presented data at the American Association for Cancer Research Drug Discovery and Development (AACR D3) conference demonstrating how ACR-2316 was rationally designed with AP3 for potent single agent activity and a superior therapeutic index

ACR-7280: Oral CDK11 Inhibitor

  • Internally-discovered development candidate prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors
  • Data showing complete tumor regression in aggressive acute myeloid leukemia (AML) xenograft models, an AP3-predicted tumor type, accepted for poster presentation at the upcoming 38th EORTC-NCI-AACR Symposium
  • Investigational New Drug (IND)-enabling studies are underway to support initial clinical development in AML and peripheral T-cell lymphoma

Anticipated Upcoming Milestones

ACR-368 Ongoing Registrational Intent Phase 2b Study

  • A prespecified simultaneous interim analysis and data update from both all-comer (biopsy-independent) serous EC arms of the ACR-368 Phase 2b study, and update of the OncoSignature-positive endometrial cancer (Arm 1) in the fourth quarter of 2026
  • Based on interim data read-out, complete enrollment of the registrational intent all-comer (biopsy-independent) serous EC Arm 3 or Arm 4 in the fourth quarter of 2026

ACR-2316

  • Complete enrollment in dose expansion phase and generate additional preclinical and clinical data to prioritize Phase 2 registrational path by mid-2027

ACR-7280

  • Submit IND filing to the FDA in the first half of 2027

ACR-525

  • Align with FDA on trial design for Phase 2 EoE study in the first quarter of 2027

PKCθ program

  • Advance promising lead candidates towards IND-enabling studies in the first half of 2027

Third Quarter 2026 Financial Results

Net loss for the quarter ended September 30, 2026 was $17.9 million compared to a net loss of $18.2 million for the same period in 2025.

Research and development expenses were $14.5 million for the quarter ended September 30, 2026, compared to $13.6 million for the same period in 2025. The difference was driven by the timing of clinical trial and related costs for ACR-368 and ACR-2316.

General and administrative expenses were $4.0 million for the quarter ended September 30, 2026, compared to $6.0 million for the same period in 2025. The difference was primarily driven by employee-related expenses, including stock-based compensation expense.

As of September 30, 2026, the company had cash, cash equivalents and investments of $77.8 million, which is expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.

About Acrivon Therapeutics
Acrivon is a clinical-stage biopharmaceutical company discovering and developing precision medicines for oncology and inflammatory diseases utilizing its proprietary Generative AI-driven, Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, including the AP3 Kinase Substrate Relationship Predictor (KaiSR) and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

In its oncology pipeline, Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer (EC). The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with EC. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.

In addition, Acrivon is leveraging its proprietary Generative AI-driven Phosphoproteomics AP3 platform for developing wholly-owned, internally discovered, co-crystallography-driven pipeline programs. These include ACR-2316, a first-in-class, potent, selective WEE1/PKMYT1 inhibitor preclinically designed for superior single-agent activity. The Phase 1/2 study of ACR-2316 is advancing in a randomized dose expansion phase in AP3-predicted tumor types. Initial data has shown a highly differentiated, favorable safety profile primarily limited to only transient neutropenia. Clinical activity has been observed across multiple heavily pretreated, AP3-predicted tumor types, including a subject with a confirmed CR in squamous non-small cell lung cancer (NSCLC), a PR in small cell lung cancer (SCLC), as well as long-lasting clinical benefit (over one year) observed in subjects with lung adenocarcinoma, tumor types not shown sensitive to current single-agent WEE1 or PKMYT1 inhibitors.

In addition, the company is advancing ACR-7280, its next AP3-enabled innovation program, a first-in-class, oral, highly selective CDK11 inhibitor development candidate, in IND-enabling studies. AP3 indication finding identified acute myeloid leukemia (AML) as a predicted sensitive tumor type, and in preclinical studies, ACR-7280 demonstrated potent anti-tumor activity and complete tumor regression in aggressive AML models.

In its immunology and inflammation (I&I) pipeline, Acrivon has ACR-525, a Phase 2-ready, oral, highly selective JAK1 inhibitor, acquired and identified based on AI-driven AP3 profiling showing favorable selectivity head-to-head against other JAK1 inhibitors, targeting eosinophilic esophagitis as a potential first indication utilizing a formulation designed for patients with difficulty swallowing. ACR-525 also has potential in inflammatory bowel disease and other autoimmune and inflammatory diseases as a single agent and in combination. Additionally, the company has a preclinical PKCθ inhibitor program, an attractive target for T-cell-driven autoimmune and inflammatory diseases, with the potential to be developed in combination with ACR-525 and other I&I therapies.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.

Acrivon intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.acrivon.com.

Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com

Alexandra Santos
asantos@wheelhouselsa.com


Acrivon Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(unaudited, in thousands)
    
 September 30, December 31,
 2026
 2025
Assets   
Cash and cash equivalents$47,535 $41,499
Investments 30,216  77,083
Other assets 7,997  11,135
Total assets$85,748 $129,717
Liabilities and Stockholders' Equity   
Liabilities$14,974 $17,201
Stockholders' Equity 70,774  112,516
Total Liabilities and Stockholders' Equity$85,748 $129,717


Acrivon Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited, in thousands, except share and per share data)
        
 Three Months Ended September 30, Nine Months Ended September 30,
  2026   2025   2026   2025 
Operating expenses:       
Research and development$14,547  $13,648  $43,557  $45,244 
General and administrative 3,971   6,039   13,531   18,754 
Total operating expenses 18,518   19,687   57,088   63,998 
Loss from operations (18,518)  (19,687)  (57,088)  (63,998)
Other income (expense), net:       
Interest income 748   1,506   2,597   5,232 
Other expense, net (127)  (53)  (412)  (154)
Total other income, net 621   1,453   2,185   5,078 
Net loss$(17,897) $(18,234) $(54,903) $(58,920)
Net loss per share - basic and diluted$(0.42) $(0.47) $(1.33) $(1.53)
Weighted-average common stock outstanding - basic and diluted 42,876,572   38,560,464   41,162,962   38,458,279 
Comprehensive loss:       
Net loss$(17,897) $(18,234) $(54,903) $(58,920)
Other comprehensive income (loss):       
Unrealized gain (loss) on available-for-sale investments, net of tax 7   6   (137)  (335)
Comprehensive loss$(17,890) $(18,228) $(55,040) $(59,255)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Acrivon Therapeutics' third-quarter 2026 financial results?

Acrivon reported a $17.897 million net loss, or $0.42 per share, compared with $18.234 million, or $0.47 per share, a year earlier. Research and development expenses rose to $14.547 million, while general and administrative expenses declined to $3.971 million.

How long does Acrivon expect its September 2026 cash balance to last?

Acrivon expects its $77.8 million in cash, cash equivalents and investments at September 30, 2026 to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.

Which treatment arms are included in Acrivon's upcoming ACR-368 interim analysis?

The prespecified simultaneous interim analysis covers both all-comer serous endometrial cancer arms: Arm 4 tests ACR-368 alone, and Arm 3 combines it with ultra-low-dose gemcitabine sensitization. These arms do not require biopsy-based selection. An update for OncoSignature-positive endometrial cancer Arm 1 is also planned for the fourth quarter of 2026.

Keep reading